First Bank & Trust Increases Stake in MEDNAX Inc (MD)

Share on StockTwits

First Bank & Trust grew its holdings in shares of MEDNAX Inc (NYSE:MD) by 18.7% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,334 shares of the company’s stock after buying an additional 526 shares during the period. First Bank & Trust’s holdings in MEDNAX were worth $90,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in MD. Oregon Public Employees Retirement Fund increased its holdings in MEDNAX by 3,200.0% in the 4th quarter. Oregon Public Employees Retirement Fund now owns 1,223,145 shares of the company’s stock worth $37,000 after acquiring an additional 1,186,080 shares in the last quarter. Bremer Trust National Association purchased a new stake in MEDNAX in the 4th quarter worth approximately $44,000. First Mercantile Trust Co. increased its holdings in MEDNAX by 13.8% in the 4th quarter. First Mercantile Trust Co. now owns 2,275 shares of the company’s stock worth $76,000 after acquiring an additional 275 shares in the last quarter. ETF Managers Group LLC increased its holdings in MEDNAX by 18.8% in the 4th quarter. ETF Managers Group LLC now owns 2,404 shares of the company’s stock worth $79,000 after acquiring an additional 381 shares in the last quarter. Finally, Ffcm LLC increased its holdings in MEDNAX by 137.0% in the 4th quarter. Ffcm LLC now owns 3,155 shares of the company’s stock worth $104,000 after acquiring an additional 1,824 shares in the last quarter. Hedge funds and other institutional investors own 94.98% of the company’s stock.

Shares of MD opened at $26.66 on Wednesday. The company has a quick ratio of 1.31, a current ratio of 1.31 and a debt-to-equity ratio of 0.64. MEDNAX Inc has a 1 year low of $26.60 and a 1 year high of $53.17. The company has a market cap of $2.42 billion, a price-to-earnings ratio of 7.60, a P/E/G ratio of 1.01 and a beta of 0.58.

MEDNAX (NYSE:MD) last announced its quarterly earnings data on Thursday, February 7th. The company reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.83 by $0.09. MEDNAX had a net margin of 7.37% and a return on equity of 10.35%. The business had revenue of $932.70 million during the quarter, compared to analyst estimates of $910.08 million. During the same period last year, the firm posted $0.87 EPS. The company’s revenue was up 2.4% on a year-over-year basis. Analysts forecast that MEDNAX Inc will post 3.43 earnings per share for the current fiscal year.

In other MEDNAX news, Director Md Pascal J. Goldschmidt sold 3,300 shares of the stock in a transaction that occurred on Wednesday, March 13th. The shares were sold at an average price of $30.40, for a total transaction of $100,320.00. Following the completion of the sale, the director now directly owns 20,821 shares of the company’s stock, valued at approximately $632,958.40. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Dominic J. Andreano sold 1,289 shares of the stock in a transaction that occurred on Wednesday, February 20th. The shares were sold at an average price of $36.22, for a total transaction of $46,687.58. Following the sale, the senior vice president now directly owns 69,069 shares of the company’s stock, valued at $2,501,679.18. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 30,279 shares of company stock valued at $988,954. Insiders own 3.40% of the company’s stock.

Several equities research analysts recently issued reports on the stock. Jefferies Financial Group reduced their target price on shares of MEDNAX from $37.00 to $31.00 and set a “hold” rating for the company in a report on Thursday, April 11th. Citigroup raised shares of MEDNAX from a “neutral” rating to a “buy” rating and set a $34.88 target price for the company in a report on Monday, January 14th. They noted that the move was a valuation call. Deutsche Bank assumed coverage on shares of MEDNAX in a report on Thursday, January 3rd. They issued a “hold” rating and a $34.00 target price for the company. Zacks Investment Research raised shares of MEDNAX from a “sell” rating to a “hold” rating in a report on Monday, January 28th. Finally, Credit Suisse Group reduced their target price on shares of MEDNAX from $44.00 to $42.00 and set an “outperform” rating for the company in a report on Wednesday, February 13th. Three equities research analysts have rated the stock with a sell rating, seven have given a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $40.44.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Macon Daily and is owned by of Macon Daily. If you are viewing this piece of content on another site, it was stolen and republished in violation of U.S. and international copyright legislation. The legal version of this piece of content can be viewed at https://macondaily.com/2019/04/17/first-bank-trust-increases-stake-in-mednax-inc-md.html.

MEDNAX Company Profile

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology and teleradiology, pediatric cardiology, and other pediatric subspecialty physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care services; and acute and chronic pain management services.

Read More: Stock Symbols, CUSIP and Other Stock Identifiers

Institutional Ownership by Quarter for MEDNAX (NYSE:MD)

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.